{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dimethyl fumarate
to a specific field?
Status:
Investigational
Source:
NCT03257592: Phase 1 Interventional Terminated Schizophrenia
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (RACEMIC)
MK-571 is a selective, orally active leukotriene D4/E4 (LTD4/E4) receptor antagonist patented by Merck Frosst Canada, Inc. for the treatment bronchoconstriction. In ex vivo models MK-571 competitively antagonizes contractions of guinea pig trachea and ileum induced by leukotriene (LT) D4 and LTE4 and contractions of human trachea induced by LTD4. MK-571 antagonizes bronchoconstriction induced in anesthetized guinea pigs by i.v. LTC4, LTD4, and LTE4 but do not block bronchoconstriction to arachidonic acid. In clinical trials, MK-571 is a potent antagonist of LTD4-induced bronchoconstriction in both normal volunteers and asthmatic patients.
Status:
Investigational
Source:
NCT02677207: Phase 2 Interventional Completed Depression
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
JNJ-39393406 is a positive allosteric alpha-7 nicotinic acetylcholine receptor modulator. It was under development for the treatment of smoking cessation, schizophrenia, Alzheimer's disease, but development for these indications was discontinued.
Status:
Investigational
Source:
NCT00862888: Phase 2 Interventional Completed Erectile Dysfunction
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
PF-00446687 is the highly selective, brain-penetrant, melanocortin 4 receptor (MC4R) agonist. PF-00446687 induced partner preferences formation in females prairie voles after a 6-h cohabitation without mating. PF-00446687 had been in phase I clinical trial for the treatment of sexual function disorders.
Status:
Investigational
Source:
NCT03899467: Phase 2 Interventional Completed Metastatic Castrate Resistant Prostate Cancer (mCRPC)
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Kintor Pharma is developing proxalutamide (developmental code GT-0918), an androgen receptor antagonist, for the treatment of metastatic castrate-resistant prostate cancer and AR-positive triple-negative breast cancer. Proxalutamide is involved in phase III clinical trials in China and in phase II in the USA for patients with metastatic castrate-resistant prostate cancer. In addition, the drug participates in phase I clinical trials for the treatment of AR-positive triple-negative breast cancer. Proxalutamide is expected to become a more effective, less toxic second-generation AR antagonist, which will have a bright prospect once it receives approval for coming on the market.
Status:
Investigational
Source:
INN:maritupirdine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02503423: Phase 1/Phase 2 Interventional Active, not recruiting Solid Tumors
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT02675452: Phase 1 Interventional Completed Relapsed or Refractory Multiple Myeloma
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02892422: Phase 3 Interventional Completed Schizophrenia
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02112695: Not Applicable Interventional Completed Sports Nutritional Sciences
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
